CoChat

Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients

Open access
Ruhnke, M., Paiva, J.A., Meersseman, W., Pachl, J., Grigoras, I., Sganga, G., Menichetti, F., Montravers, P., Auzinger, G., Dimopoulos, G., Borges Sà, M., Miller, P.J., Marĉek, T., Kantecki, M. · 2012 · Clinical Microbiology and Infection
Cited by 58

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

A prospective, multicentre, phase IIIb study with an exploratory, open-label design was conducted to evaluate efficacy and safety of anidulafungin for the treatment of candidaemia/invasive candidiasis (C/IC) in specific ICU patient populations. Adult ICU patients with confirmed C/IC meeting ≥ 1 of the following criteria were enrolled: post-abdominal surgery, solid tumour, renal/hepatic insufficiency, solid organ transplant, neutropaenia, and age ≥ 65 years. Patients received anidulafungin (200 mg on day 1, 100 mg/day thereafter) for 10-42 days, optionally followed by oral voriconazole/fluconazole. The primary efficacy endpoint was global (clinical and microbiological) response at the end of all therapy (EOT). Secondary endpoints included global response at the end of intravenous therapy (EOIVT) and at 2 and 6 weeks post-EOT, survival at day 90, and incidence of adverse events (AEs). The primary efficacy analysis was performed in the modified intent-to-treat (MITT) population, excluding unknown/missing responses. The safety and MITT populations consisted of 216 and 170 patients, respectively. The most common pathogens were Candida albicans (55.9%), C. glabrata (14.7%) and C. parapsilosis (10.0%). Global success was 69.5% (107/154; 95% CI, 61.6-76.6) at EOT, 70.7% (111/157) at EOIVT, 60.2% (77/128) at 2 weeks post-EOT, and 50.5% (55/109) at 6 weeks post-EOT. When unknown/missing responses were included as failures, the respective success rates were 62.9%, 65.3%, 45.3% and 32.4%. Survival at day 90 was 53.8%. Treatment-related AEs occurred in 33/216 (15.3%) patients, four (1.9%) of whom had serious AEs. Anidulafungin was effective, safe and well tolerated for the treatment of C/IC in selected groups of ICU patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1469-0691.2012.03784.x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 58

Metadata

Authors
Ruhnke, M., Paiva, J. A., Meersseman, W., Pachl, J., Grigoras, I., Sganga, G., Menichetti, F., Montravers, P., Auzinger, G., Dimopoulos, G., Borges Sà, M., Miller, P. J., Marĉek, T., & Kantecki, M.
Venue
Clinical Microbiology and Infection
Publisher
Elsevier BV
Published
2012-07
Volume
18
Issue
7
Pages
680-687
ISSN
1198-743X (ISSN-L)
OpenAlex
W1485575759
Cited by
58
References
9
FWCI
4.86
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients. https://app.cochat.ai/papers/10.1111/j.1469-0691.2012.03784.x
The paper
Ruhnke, M., Paiva, J. A., Meersseman, W., Pachl, J., Grigoras, I., Sganga, G., Menichetti, F., Montravers, P., Auzinger, G., Dimopoulos, G., Borges Sà, M., Miller, P. J., Marĉek, T., & Kantecki, M. (2012). Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients. Clinical Microbiology and Infection. https://doi.org/10.1111/j.1469-0691.2012.03784.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.